Terms: = Ovarian cancer AND FOXO3, FKHRL1, 2309, ENSG00000118689, MGC31925, MGC12739, FOXO2, FOXO3A, O43524, AF6q21, FKHRL1P2, DKFZp781A0677 AND Clinical Outcome
3 results:
1. Pancancer analysis of SKA1 mutation and its association with the diagnosis and prognosis of human cancers.
Lan H; Yuan J; Zhang R; Jiang B; Li Q; Huang Z; Chen P; Xiang H; Zeng X; Xiao S
Genomics; 2023 Mar; 115(2):110554. PubMed ID: 36587749
[TBL] [Abstract] [Full Text] [Related]
2. Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers.
Siu MK; Wong ES; Kong DS; Chan HY; Jiang L; Wong OG; Lam EW; Chan KK; Ngan HY; Le XF; Cheung AN
Oncogene; 2013 Jul; 32(30):3500-9. PubMed ID: 22945654
[TBL] [Abstract] [Full Text] [Related]
3. Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma.
McMillen BD; Aponte MM; Liu Z; Helenowski IB; Scholtens DM; Buttin BM; Wei JJ
Mod Pathol; 2012 Dec; 25(12):1644-53. PubMed ID: 22790015
[TBL] [Abstract] [Full Text] [Related]
